Lelipel 4 mg 14 sachets

Lelipel 4 mg 14 sachets

Compound:

Each sachet contains:
Montelukast sodium 4.2 mg, equivalent to montelukast 4 mg.
Auxiliary components:
Mannitol, hydroxypropyl cellulose, magnesium stearate.

Properties:

• Leukotriene receptor antagonist.
• Montelukast binds with high selectivity and chemical affinity to CysLT1 receptors (instead of other pharmacologically important airway receptors such as prostaglandin, cholinergic or β-adrenergic receptors).
• Montelukast inhibits the physiological action of the cisgeinyl leukotrienes LTC4, LTD4 and LTE4 by binding to the CysLT1 receptors without stimulating these receptors. 
• Montelukast inhibits CysLT1 receptors in the epithelium of the respiratory tract, thus simultaneously possessing the ability to inhibit bronchospasm caused by inhalation of LTD4 in patients with bronchial asthma.
• Montelukast causes bronchodilation within 2 hours of oral administration and may supplement bronchodilation induced by beta2-agonists.

Indications:

• Prevention and long-term treatment of bronchial asthma, including:
• prevention of day and night symptoms of the disease; 
• treatment of bronchial asthma in patients with hypersensitivity to acetylsalicylic acid; 
• prevention of exercise-induced bronchospasm.
• Relief of daytime and nighttime symptoms of seasonal allergic rhinitis.

Dosage and administration:

• Montelukast is taken by mouth.
• Children from 2 to 5 years old take 4 mg (1 sachet) per day.
• Children from 6 months to 2 years of age to relieve asthma take 1 sachet of 4 mg once a day.
• It is necessary to strictly observe the regimen of therapy. 
• It is recommended to continue treatment even when significant clinical improvement is achieved.

Contraindications:

Hypersensitivity to montelukast; children’s age – depending on the dosage form.

Precautionary measures:

• The efficacy of oral montelukast in the treatment of acute asthma attacks has not been established.
• Therefore, oral montelukast is not recommended for the treatment of acute asthma attacks.
• Patients should be instructed to carry emergency asthma medications (short-acting inhaled beta2-agonists) with them at all times.
• The dose of inhaled corticosteroids used concomitantly with montelukast can be gradually reduced under the supervision of a physician, however, a sharp replacement of inhaled or oral corticosteroids with montelukast cannot be carried out.

Side effects:

• Infectious diseases: very often – infections of the upper respiratory tract.
• From the nervous system: infrequently – headache, dizziness, drowsiness, paresthesia / hypoesthesia, convulsions.
• From the side of the cardiovascular system: rarely – palpitations.
• From the respiratory system: infrequently – nosebleeds; very rarely – pulmonary eosinophilia.
• From the digestive system: often – diarrhea, nausea, vomiting.
• From the side of the liver and biliary tract: often – an increase in the activity of ALT and ACT.

Storage method:

Store at a temperature not exceeding 30 degrees.

Package:

The cardboard box contains 14 sachets with granules, paper instructions.